Amber Salzman

Bio:

Amber Salzman, Ph.D., is a seasoned leader with over 30 years of experience in developing therapies. She began her career at GlaxoSmithKline (GSK), where she was a member of the research and development executive team and led drug development, overseeing global clinical trials involving more than 30,000 patients. In 2009, she transitioned from GSK to lead Cardiokine until its acquisition. Amber then co-founded a gene therapy company that merged with Avalanche Biotechnologies to create Adverum (NASDAQ: ADVM). After leading ADVM, she took on the leadership of Ohana, focusing on improving IVF outcomes. Recognizing Epicrispr’s potential to address the limitations of genetic medicine, Amber became CEO, developing next-generation therapies to control gene expression. 
While at GSK, she co-founded the Stop ALD Foundation, advocating for patients with rare diseases, and initiated research that led to the commercialization of a gene therapy for ALD. Amber also serves on the boards of Osler Diagnostics and AviadoBio.